Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.

Other research analysts have also issued research reports about the stock. BidaskClub lowered shares of Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 16th. Citigroup lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $32.00 to $19.00 in a research report on Wednesday, August 16th. Credit Suisse Group reissued an “outperform” rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries in a research report on Wednesday, August 9th. Cantor Fitzgerald set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, September 11th. Finally, Zacks Investment Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 9th. Seven equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Teva Pharmaceutical Industries presently has an average rating of “Hold” and a consensus price target of $21.65.

Teva Pharmaceutical Industries (NYSE TEVA) opened at $14.32 on Tuesday. The company has a market cap of $15,290.80, a PE ratio of 3.48 and a beta of 0.55. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $38.31.

A number of institutional investors have recently modified their holdings of TEVA. Security National Bank of Sioux City Iowa IA grew its stake in shares of Teva Pharmaceutical Industries by 0.4% during the second quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock valued at $724,000 after purchasing an additional 87 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in shares of Teva Pharmaceutical Industries by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after purchasing an additional 94 shares during the last quarter. CIBC Asset Management Inc grew its stake in shares of Teva Pharmaceutical Industries by 0.3% during the second quarter. CIBC Asset Management Inc now owns 65,534 shares of the company’s stock valued at $2,177,000 after purchasing an additional 178 shares during the last quarter. Sheaff Brock Investment Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 3.6% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock valued at $279,000 after purchasing an additional 294 shares during the last quarter. Finally, IFP Advisors Inc grew its stake in shares of Teva Pharmaceutical Industries by 3.8% during the second quarter. IFP Advisors Inc now owns 12,629 shares of the company’s stock valued at $420,000 after purchasing an additional 459 shares during the last quarter. 52.05% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This article was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://theolympiareport.com/2017/12/07/valuengine-upgrades-teva-pharmaceutical-industries-teva-to-buy.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.